An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis

Enrolling by invitation · Phase 2

Conditions studied: Psychosis Associated With Alzheimer's Disease

In brief

ML-007C-MA-222 is a 52-week, flexible-dose, open-label extension study designed to evaluate the long-term safety, tolerability, and effectiveness of ML007C-MA in participants with ADP who have completed the antecedent study (ie, Study ML-007C-MA-221).

Key facts

Study ID

NCT07459660

Run by

MapLight Therapeutics

People needed

210

Starts

2026-03-25

Expected to finish

2029-03-01

Last updated by the study team

2026-08-07

Who can join

Age: 55 and older, up to 91. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Willing and able to provide written informed consent, or, if deemed lacking in the capacity to provide informed consent, the following requirements for consent must be met:
• The participant's LAR must provide written informed consent. AND
• The participant will provide informed assent.
• Has completed the Double-Blind Treatment Period of an antecedent study with ML-007C-MA (ie, ML-007C-MA-221).
• May benefit from long-term therapy with open-label ML-007C-MA treatment, in the judgment of the investigator.
• Has a designated study care partner who is in contact with the participant frequently enough to accurately report on the participant's symptoms and adherence to study drug.
• Resides in a stable living environment (eg, home, residential assisted living, or nursing home facility) and is expected to remain in the living situation throughout the study.

You may not qualify if…

• Under the care of hospice, bed-bound, or receiving end-of-life palliative care.
• Requires treatment with protocol-defined prohibited medications.
• Has developed a new or worsening medical comorbidity during or since the antecedent study that, in the opinion of the investigator and/or medical monitor, would compromise participant safety, interfere with the participant's ability to comply with study procedures, would preclude obtaining voluntary consent/assent, and/or would substantially impair the evaluation of study assessments.
• Has or had a clinically significant abnormal physical examination, vital sign, ECG or clinical laboratory safety result during or since the antecedent study that would compromise participant safety, interfere with the participant's ability to comply with study procedures, and/or would confound the interpretation of the outcome measures in the study in the opinion of the investigator.
• Has developed an allergy or other intolerance to ML-007C-MA, its active ingredients or their excipients since the antecedent study.
• Has an elevated risk of suicidal behavior.

Where it is running

• Clinical Site — Anaheim, California, United States
• Clinical Site — Doral, Florida, United States
• Clinical Site — Miami, Florida, United States
• Clinical Site — Miami, Florida, United States
• Clinical Site — Miami Gardens, Florida, United States
• Clinical Site — Orlando, Florida, United States
• Clinical Site — Pernik, Pernik, Bulgaria
• Clinical Site — Toulouse, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.